Creating a new generation of small molecule protease inhibitors

2017 News Releases

Keyword Search
 
DateTitle 
03/16/17KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
–  Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE – – Intravitreal DME Program Remains on Track for Phase 2 in 2017 – – Company Expects to be Well-Funded Through Data Inflection Points – CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 16, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,... 
Printer Friendly Version
03/09/17KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical
Executive Brings Strong Medical and Regulatory Affairs Background and Deep HAE ExpertiseCAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 09, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the appointment of Andreas Maetzel, M.D., M.Sc., Ph.D, to the role of Senior Vice President, Medical."Andreas brings a wealth... 
Printer Friendly Version